What are the different types of long‑acting β2‑agonists (LABAs) used in respiratory disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Different Types of Long-Acting β2-Agonists (LABAs)

LABAs are categorized into twice-daily agents (formoterol and salmeterol) and once-daily ultra-LABAs (indacaterol, olodaterol, and vilanterol), with formoterol being a full agonist offering faster onset compared to salmeterol's partial agonist profile.

Twice-Daily LABAs

Formoterol

  • Full agonist with high intrinsic efficacy 1, 2
  • Fast onset of action (within minutes), allowing use as both maintenance and reliever therapy 2
  • Maintains bronchodilatory activity even when β2-adrenoceptor availability is reduced (such as in inflamed airways) 2
  • Used in GINA Track 1 as ICS-formoterol combination for maintenance and reliever therapy (MART) 3
  • Available formulations include budesonide-formoterol 160/4.5 mcg 3

Salmeterol

  • Partial agonist with lower intrinsic efficacy 1, 2
  • Slower onset of action compared to formoterol 2
  • May be less effective in inflamed airways due to partial agonism 2
  • 12-hour duration of action 4

Once-Daily Ultra-LABAs

Indacaterol

  • 24-hour duration of bronchodilation 4
  • Fast onset of action 4
  • Improves lung function compared to placebo and other long-acting bronchodilators 4
  • Most clinically advanced once-daily LABA 4

Olodaterol

  • 24-hour duration of action 1
  • Used in COPD management 1

Vilanterol

  • 24-hour duration of bronchodilation 1, 4
  • Available in combination products 4

Other Agents in Development

  • Carmoterol, arformoterol, and various GSK compounds (GSK-159797, GSK-597901, GSK-159802, GSK-642444, GSK-678007) are under investigation 4, 5, 6

Clinical Implications by Disease

For Asthma

  • Formoterol-containing ICS combinations are preferred for MART regimens across all treatment steps 3
  • The same low-dose ICS-formoterol formulation can be used from Step 1 through Step 5 3
  • LABAs should never be used as monotherapy in asthma; always combined with ICS 3

For COPD

  • All LABA types (formoterol, salmeterol, indacaterol, olodaterol, vilanterol) improve symptoms, lung function, and reduce exacerbations 1
  • LAMA/LABA dual therapy is preferred over ICS/LABA for most COPD patients due to superior lung function improvements and lower pneumonia risk 7
  • Once-daily LABAs offer potential compliance advantages through simplified dosing 4

Key Pharmacological Distinctions

The critical difference between formoterol and salmeterol lies in receptor activity: formoterol's full agonism provides consistent bronchodilation even in inflamed airways with reduced receptor availability, while salmeterol's partial agonism may result in diminished effectiveness under the same conditions 2. This makes formoterol particularly advantageous for patients with active inflammation or during exacerbations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.